SAVA - Cassava Sciences, Inc.
| 前收市價 | 23.57 |
| 開市 | 23.61 |
| 買盤 | 22.65 x 3200 |
| 賣出價 | 22.66 x 1300 |
| 今日波幅 | 22.56 - 23.70 |
| 52 週波幅 | 13.84 - 51.59 |
| 成交量 | |
| 平均成交量 | 712,120 |
| 市值 | 944.789M |
| Beta 值 (5 年，每月) | -0.14 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.99 |
| 業績公佈日 | 2023年8月01日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2012年12月13日 |
| 1 年預測目標價 | 112.00 |
InvestorPlace3 Biotech Stocks to Avoid Like the Plague
Biotech stocks have gotten caught up in the broader technology sector sell-off. The benchmark iShares Biotechnology ETF (NYSEARCA:IBB) has fallen from a peak of $175 in 2021 to just $130 today. There are few signs of a biotech stock bubble at this point. That said, even with the sector at an overall discount, that’s not an all-clear for the whole sector. Many of the worst biotech stocks either have a drug prospect that is unlikely to get FDA approval or one that simply never garners much commerc
InvestorPlace3 Short-Squeeze Stocks to Keep on Your Radar
Short-squeezes have been making headlines in stock trading as an increasingly popular phenomenon. A short squeeze occurs when investors who have bet against a company’s stock (by “shorting” it) are forced to buy back their shares to cut their losses. This sudden buying activity can lead to a surge in the stock’s price, causing a chain reaction of buying among other investors and a significant price increase. Thus, various short-squeeze stocks can see outsized gains in short order. That said, lik
InvestorPlace3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End
One in every nine seniors is living with Alzheimer’s disease, and the race to cure it is worth big money. While the FDA has approved some Alzheimer’s disease drugs, these can only slow the progression, not halt or reverse it. Despite lacking efficacy, Alzheimer’s disease drugs currently charge exorbitant amounts because, for sufferers, there is no other choice. Since drugs are expensive and non-curative, the market is crying out for new drugs and ideas. That’s precisely what these companies are
BenzingaCassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results
Editor's note: The headline of this story has been updated to more accurately reflect the results of the Cassava Sciences Phase 2 trial for simufilam. Cassava Sciences Inc (NASDAQ: SAVA) announced topline Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. Study participants were administered open-label simufilam tablets 100mg twice daily for one year or more. Endpoints were measured at baseline (study entry) and month 12. In the mild sub-group, ADAS-Cog (cog
InvestorPlace7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022
High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal. Categories include bribery, fraud, stock manipulation, and even non-criminal charges, such as negligent and strict liability torts. In some cases, the “sca
BenzingaLexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k
- InvestorPlace
What the Latest Controversy Really Means for SAVA Stock
As I discussed in my last article on Cassava Sciences (NASDAQ:SAVA), controversy continues to weigh on the performance of SAVA stock. Over the past week, shares in the clinical-stage biotech firm have traded wildly. First pushed lower by a perceived potential bombshell, shares then zoomed higher, as the company took an aggressive step in fighting back against the short-seller that management believes are behind the much-discussed data manipulation allegations laid against Cassava. So, what is th
- InvestorPlace
A New Study Makes Cassava Sciences Stock an Interesting Buy
Since making some big moves last month Cassava Sciences (NASDAQ:SAVA) stock has largely traded sideways. Yet while SAVA stock has been acting less wild, don’t blame it on a lack of new developments. As InvestorPlace’s Eddie Pan reported Oct. 13, the biotech firm has announced plans to hold an open-label study for simufilam, its Alzheimer’s treatment candidate.InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s not entirely surprising that this latest news isn’t having much of an
- InvestorPlace
Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock
Sometimes, financial traders might forget that Cassava Sciences (NASDAQ:SAVA) stock is, as the company’s name suggests, all about the science. That’s because the media will distract you with reports of data manipulation claims. Don’t misunderstand – it’s important to know about these allegations. Yet, SAVA stock investors should keep their eyes on the prize, and that prize is a proposed Alzheimer’s disease treatment. Cassava Sciences is an ambitious clinical-stage biotechnology company. It’s a t
- InvestorPlace
2 Signals to Watch Before Buying SAVA Stock
Cassava Sciences (NASDAQ:SAVA) stock took off once again during September. Rumors about the Securities and Exchange Commission (or SEC) clearing its investigation of the scandal-tarnished biotech firm resulted in a big spike for SAVA stock on Sept. 22. While partially pulling back immediately after, as Cassava’s management dispelled the rumors, news indirectly related to the company’s efforts to bring its Alzheimer’s treatment candidate, Simulfilam, to market, helped to briefly sustain the rally
- InvestorPlace
How High Can SAVA Stock Go Once the Controversy Clears?
Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ:SAVA). As the biopharmaceutical company contends with data-manipulation allegations, traders have to figure out what to do with SAVA stock. There may be evidence that the case against Cassava will be closed soon, though — and that would be bullish for Cassava Sciences. Cassava Sciences is what I call a “ride or die” k
- InvestorPlace
Caution! It’s Not Safe to Jump on the SAVA Stock Hype Train.
There’s been some drama surrounding Cassava Sciences (NASDAQ:SAVA) recently. First, there was a report stating that the Securities and Exchange Commission, or SEC, cleared Cassava Sciences of charges of manipulating research results. Not long afterward, however, Cassava disputed the legitimacy of that report. These twists and turns in the ongoing story make it difficult to recommend SAVA stock with confidence now. Let’s start with the basics. Cassava Sciences is a biotechnology firm with a prima
Insider Monkey10 Most Shorted Stocks in September
In this article, we discuss the 10 most shorted stocks to watch in September. If you want to skip our analysis on short selling, go directly to the 5 Most Shorted Stocks in September. In the past two years, short squeezes have become a hot and a controversial topic on Wall Street. Reddit became a […]
Insider Monkey16 Best Penny Stocks to Buy Now
In this article, we discuss the 16 best penny stocks to buy now. If you want to read about some more penny stocks with strong business fundamentals, check out the 5 Best Penny Stocks to Buy Now. Investors are taking refuge in holding cash and liquidating their stock portfolios to weather out the impact of rising […]
BenzingaCassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims
Journal of Prevention of Alzheimer's Disease (JPAD) informed Cassava Sciences Inc (NASDAQ: SAVA) about no convincing evidence to support data manipulation allegations in a 2020 paper on simufilam co-authored by the company's personnel and its science collaborators. Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain. "From the onset, I have said that allegations of research misconduct ar
Yahoo FinanceTop after-hours movers: Apple, Cassava Sciences, Canoo, Digital World Acquisition Corp.
Top trending after-hours tickers on Yahoo Finance.
InvestorPlace10 Stocks to Sell Before They Die
This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here. Source: Shutterstock Growing up, my family’s hamburger grilling looked like this. Ground beef? Check.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salt, pepper and spices? Of course. Then add bell peppers, onions, saltine crackers and an egg for good measure? Umm… That too. It was only after the interne
BenzingaCassava Sciences Shares Plunge After Criminal Investigation Report
The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc (NASDAQ: SAVA) on whether it manipulated research results for its investigational Alzheimer's drug, Reuters reported citing two people familiar with the inquiry. "To be clear: Cassava Sciences vehemently denies any and all allegations of wrongdoing," said Kate Watson Moss, a lawyer representing Cassava. The company "has never been charged with a crime, and for a good reason - Cassava Sciences has never enga
InvestorPlace7 Meme Stocks Trading at a Massive Discount Right Now
It’s safe to say the “meme stocks” phenomenon is fully in the rearview mirror. “Meme kings” like GameStop (NYSE:GME), BlackBerry (NYSE:BB) and AMC Entertainment (NYSE:AMC) have held onto a fair chunk of their “to the moon” gains. Secondary names, though? They’ve experienced the opposite, as most have tumbled to new lows. However, there may be an opportunity here, with the scores of meme stocks trading at a discount. Admittedly, most of these meme plays had no business trading at the lofty highs